Literature DB >> 24240115

Pertuzumab protects the achilles' heel of trastuzumab--emtansine.

William R Gwin1, Neil L Spector.   

Abstract

Trastuzumab emtansine (T-DM1) represents a significant advancement in the treatment of HER2(+) breast cancers. Its clinical efficacy however will be limited by the development of therapeutic resistance. In this report, the HER3 ligand neuregulin is shown to mediate T-DM1 resistance, which was overcome by administration of pertuzumab, a steric inhibitor of HER2 dimerization. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24240115     DOI： 10.1158/1078-0432.CCR-13-2626

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  4 in total

1.  A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.

Authors:  Nandini Dey; Casey Williams; Brain Leyland-Jones; Pradip De
Journal:  Am J Transl Res       Date:  2015-04-15       Impact factor: 4.060

2.  Evolving Strategies for Target Selection for Antibody-Drug Conjugates.

Authors:  Marc Damelin; Wenyan Zhong; Jeremy Myers; Puja Sapra
Journal:  Pharm Res       Date:  2015-01-15       Impact factor: 4.580

Review 3.  Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine.

Authors:  Saeed Sadeghi; Olga Olevsky; Sara A Hurvitz
Journal:  Pharmgenomics Pers Med       Date:  2014-10-15

4.  Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial.

Authors:  Amy S Clark; Christina Yau; Denise M Wolf; Emanuel F Petricoin; Laura J van 't Veer; Douglas Yee; Stacy L Moulder; Anne M Wallace; A Jo Chien; Claudine Isaacs; Judy C Boughey; Kathy S Albain; Kathleen Kemmer; Barbara B Haley; Hyo S Han; Andres Forero-Torres; Anthony Elias; Julie E Lang; Erin D Ellis; Rachel Yung; Debu Tripathy; Rita Nanda; Julia D Wulfkuhle; Lamorna Brown-Swigart; Rosa I Gallagher; Teresa Helsten; Erin Roesch; Cheryl A Ewing; Michael Alvarado; Erin P Crane; Meredith Buxton; Julia L Clennell; Melissa Paoloni; Smita M Asare; Amy Wilson; Gillian L Hirst; Ruby Singhrao; Katherine Steeg; Adam Asare; Jeffrey B Matthews; Scott Berry; Ashish Sanil; Michelle Melisko; Jane Perlmutter; Hope S Rugo; Richard B Schwab; W Fraser Symmans; Nola M Hylton; Donald A Berry; Laura J Esserman; Angela M DeMichele
Journal:  Nat Commun       Date:  2021-11-05       Impact factor: 14.919
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.